Please assess the completion status of the following clinical trial:

Trial Title: Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and females aged 40-75 years with COPD and symptoms such as cough, sputum production, and shortness of breath.~* Smoking history of at least 10 pack years~* FEV1 less than 65% of the predicted normal value and at least 0.75 L~* Pre-bronchodilator FEV1/FVC less than 70%~Exclusion Criteria:~* A history of asthma or COPD diagnosis before the age of 40~* Hospitalization for COPD exacerbation within the previous 6 weeks~* Respiratory tract infection within 6 weeks~* Use of long-term oxygen therapy~* Diabetes type I or uncontrolled diabetes type II~* Clinically relevant laboratory abnormality or clinically significant condition~* Corrected QT interval (QTc) above 430 ms for males and 450 ms for females, or a history of QTc prolongation. Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).